Prevision Medicine
Tests a patient's living tumour cells against 100+ drugs and combinations before treatment, with automated microscopy and image analysis, so oncologists can rank drugs by how selectively they kill cancer cells.
Money and evidence
Latest round, Seed, 2026-09-24: the record then held 1 research entry, highest level 4. The first research entry is dated 2024-09-20; the highest level so far is 4 (Tested in the physical world).
Rounds and research, on one timeline
- 2026-09-24SeedRound
$5.4M
For: commercialise its functional precision-medicine test, obtain regulatory clearances and reimbursement coverage, and expand operations across Europe
Commercial roll-out
Valuation and closing date not disclosed; unnamed angel investors also took part.
Lead · ACE VenturesGoHub VenturesSICTIC
By this date the record held 1 research entry, highest level 4
Announced by the company · previsionmedicine.com ↗On the timeline →
- 2024-09-20Research
Level 4 · Tested in the physical world
A patient-tissue drug screen plus machine learning finds an antidepressant that boosts glioblastoma chemotherapy in animals
Per Prevision's team page, co-founder Snijder's lab built this screening method, which Prevision sells. The drug benefit shown is in animals, not patients.
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.